Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and Cabazitaxel in Metastatic Castration Resistant Prostate Cancer
NCT02522715Phase 2Active, not recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Aug 2015
- Primary completion
- Oct 2019
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel ginsenoside liposome injection and enzalutamide in prostate cancer (PCa), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities up to 42 days and PSA Response 1, Defined as >= 90% PSA Decline From Baseline up to 68 weeks. Started Aug 2015; status: active, not recruiting.
02
Drugs
cabazitaxel ginsenoside liposome injectionenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02522715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02522715.